ExpreS2ion Biotechnologies - Presentation of Q3 2025 Earnings Release
You can already now sign up for the event and send in your questions. You don’t have to participate live to submit your questions for the event.
ExpreS2ion Biotechnologies is expected to release its results for the first nine months of 2025 on 13 November 2025. Later the same day at 11:00 CET, the management team will present the financial results and key achievements in a live online presentation. The presentation will be followed by a Q&A session.
Since the H1 2025 report, the company has announced the first early results from the ongoing Phase 1 trial of ES2B-C001, a novel immunotherapeutic vaccine candidate targeting HER2-expressing breast cancer. The data indicate that the vaccine triggers a significant immune response. Furthermore, the TO11 warrant program was completed, resulting in SEK 11.8 million in new capital before issue costs.
In addition to the financial results for the first nine months, the discussion may focus on the company’s capital position and financial runway following the completion of the warrant program, as well as an update on the development timelines for the ES2B-C001 candidate.
ExpreS2ion Biotechnologies is a Danish biotechnology company focused on the development of vaccines using its proprietary ExpreS2 production platform in combination with AdaptVac’s VLP technology.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 13.21 CEST, 13 October 2025.
